SeltaSquare Showcases AI-Based Pharmacovigilance Services at '2024 KIC'
페이지 정보
본문
SeltaSquare (CEO: Shin Min-kyung) announced on the 8th that it presented its full lineup of AI-based full-lifecycle PV (pharmacovigilance) solutions and end-to-end PV services at the 2024 KoNECT International Conference (2024 KIC), held in Yongsan, Seoul.
Hosted by the Korea National Enterprise for Clinical Trials and the Ministry of Health and Welfare, the 2024 KIC is Asia's largest clinical trial conference, now in its 10th year. The event was attended by approximately 1,400 participants, including domestic and international bio specialists, pharmaceutical developers, clinical researchers, regulatory authority representatives, and clinical CRO professionals.
At the conference, SeltaSquare showcased a suite of solutions applicable across the full lifecycle of pharmacovigilance operations, including SELTA-WAVE (Safety Data Entry automation solution), SELTA-LITUS (literature search automation solution), SELTA-OCTO (AI-powered MedDRA Coder), and SELTA-TUBE (product renewal analysis and table automation solution).
In addition, during the pharmacovigilance session, the company introduced strategies for navigating evolving PV regulations, presenting approaches and competitive advantages enabled by AI technology for managing big data.
A company representative noted: "Following our presentation at the '2024 DIA Asia Meeting' on innovative tools to accelerate drug development for Asian patients, we once again offered AI-driven insights and capabilities applicable to both pharmacovigilance and new drug development at this conference."
CEO Shin Min-kyung stated: "We will continue to expand the application scope of our full-lifecycle AI PV solutions, and will lead the digital transformation of pharmacovigilance through ongoing information sharing and company-led education initiatives in the PV field."
SeltaSquare recently entered the global market through a partnership with Oracle Argus, and is continuing to advance its proprietary AI technologies, having received a patent for a "Method and Apparatus for Determining Hallucination Scores in Language Processing System Models."
Read the Original Article on Money Today: SeltaSquare Showcases AI-Based Pharmacovigilance Services at '2024 KIC'
